Singapore Pediatric Langerhans Cell Histiocytosis Zoledronate Treatment Outcomes

Singapore's National University Hospital retrospectively evaluated eight children with bone-involved Langerhans cell histiocytosis treated with intravenous zoledronate between January 2020 and December 2025. The dataset records patient demographics, prior treatments, pain response, radiologic outcomes, and adverse effects. It was authored by Jann Adriel Sy and published on figshare in April 2026.

Use Cases

• Analyze pain response rates based on clinical improvement outcomes
• Evaluate radiologic outcomes based on lesion stability or sclerosis data
• Associate adverse effects with zoledronate treatment based on recorded events
• Compare treatment efficacy across patient subgroups based on heterogeneous prior treatment exposure

Strengths

• All 4 symptomatic patients experienced pain improvement (100%)
• Median time to pain improvement was 18 days post-infusion
• Treatment was well tolerated; only transient fever occurred in 4 patients
• Data covers a 5-year period from January 2020 to December 2025

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Dataset is small (6.1 MB), limiting statistical power

Provenance

Source

National University Hospital, Singapore

Collection Method

Retrospective clinical evaluation

Time Range

January 2020 to December 2025

Freshness

Last updated 2026-04-29 05:57:22

Geography

Singapore